As for the distinctive potential of the gene in non-small cell lung cancer, researchers from MD Anderson Cancer reported in 2018 that HLA-DRA has different expression levels in the normal and tumor tissue sections in clinical FFPE samples [52]. This evidence concerns the gene HLA-DRA and non-small cell lung carcinoma.